Bradley Radoff plans to nominate three directors for Atea Pharmaceuticals' 2025 Annual Stockholders Meeting

From GlobeNewswire: 2025-03-21 17:54:00

Atea Pharmaceuticals, Inc. received notice from Bradley L. Radoff about his intention to nominate three director candidates for the 2025 Annual Meeting of Stockholders. The Board of Directors and management will evaluate the candidates, with Evercore as financial advisor and Latham & Watkins LLP as legal counsel. Atea focuses on developing oral antiviral therapies for serious viral infections, currently working on a regimen for HCV. More information can be found on Atea’s website. A definitive proxy statement for the 2025 meeting will be filed with the SEC. Investors and security holders should review these documents for important information. Atea, its directors, and executive officers may participate in the solicitation of proxies. Contact SVP, Investor Relations and Corporate Communications, Jonae Barnes for more information.



Read more at GlobeNewswire: Atea Pharmaceuticals Issues Statement Regarding Director